Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $402000.0.

  • Utah Medical Products' Asset Writedowns and Impairment changed N/A to $402000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $397000.0, marking a year-over-year increase of 506250.0%. This contributed to the annual value of -$4000.0 for FY2024, which is 8787.88% up from last year.
  • Latest data reveals that Utah Medical Products reported Asset Writedowns and Impairment of $402000.0 as of Q3 2025.
  • In the past 5 years, Utah Medical Products' Asset Writedowns and Impairment registered a high of $402000.0 during Q3 2025, and its lowest value of -$27000.0 during Q2 2023.
  • For the 5-year period, Utah Medical Products' Asset Writedowns and Impairment averaged around $22888.9, with its median value being $2000.0 (2021).
  • In the last 5 years, Utah Medical Products' Asset Writedowns and Impairment surged by 50000.0% in 2021 and then crashed by 90000.0% in 2024.
  • Over the past 5 years, Utah Medical Products' Asset Writedowns and Impairment (Quarter) stood at $4000.0 in 2021, then soared by 125.0% to $9000.0 in 2022, then crashed by 122.22% to -$2000.0 in 2023, then surged by 200.0% to $2000.0 in 2024, then soared by 20000.0% to $402000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $402000.0 for Q3 2025, versus $2000.0 for Q2 2025 and -$9000.0 for Q1 2025.